Entinostat plus pyrotinib and hormone therapy for advanced breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new combination of two targeted drugs (entinostat and pyrotinib) with hormone therapy for people with advanced, triple-positive breast cancer whose disease has progressed after trastuzumab (Herceptin). The goal is to see if this approach works better than current options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 75 years old, either before or after menopause.
- Your breast cancer is both hormone receptor-positive (HR+) and HER2-positive.
- Your cancer is locally advanced (cannot be removed by surgery) or has spread to other parts of the body.
- You have already been treated with trastuzumab and a taxane chemotherapy drug.
- You have had 1 or 2 prior treatments for your advanced cancer.
- You have at least one tumor that can be measured on scans, and your overall health is good (ECOG score 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—pyrotinib, trastuzumab, and chemotherapy—to treat HER2-positive breast cancer that has not been treated before. HER2 is a protein found on some cancer cells; blocking it may help stop the cancer from growing.
This trial tests a combination of two targeted medicines (pyrotinib and trastuzumab) with chemotherapy to treat HER2-positive advanced breast cancer that has returned or spread after stopping trastuzumab.
This trial tests adding entinostat (a drug that may help hormone therapy work better) to anlotinib or fulvestrant for people with HR-positive, HER2-negative advanced breast cancer that has worsened after prior hormone therapy and a CDK4/6 inhibitor. It aims to find a new treatment option for those who cannot use chemotherapy yet.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) as maintenance therapy to keep HER2-positive breast cancer that has spread under control. It is for women who have already received some first-line treatment and are stable enough to continue therapy.
This trial tests whether giving a combination of two targeted drugs (pyrotinib and trastuzumab) along with standard chemotherapy before surgery can work better for HER2-positive breast cancer. It is for women whose cancer has not spread to distant organs and who have not yet had treatment for their cancer.
This trial tests a combination of three targeted drugs for a type of advanced breast cancer that is both ER-positive and HER2-positive. The goal is to see if adding these two new drugs to standard hormone therapy can help shrink or control the cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.